Akari Therapeutics, Plc (AKTX) P/E Ratio History
Insufficient DataInsufficient historical P/E data to classify valuation. · Data 2026–2026
Loading P/E history...
P/E Ratio Analysis
As of June 30, 2026, Akari Therapeutics, Plc (AKTX) trades at a price-to-earnings ratio of -0.0x, with a stock price of $9.69 and trailing twelve-month earnings per share of $-1333.08.
Compared to the Healthcare sector median P/E of 22.9x, AKTX trades at a 100% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 191.6x.
Relative to the broader market, AKTX trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our AKTX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
AKTX Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
AKTX P/E vs Peers
Immunology and Inflammation Therapies peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $5B | 17.9 | 0.45Best | -5% | |
| $2B | 7.0Lowest | 0.68 | +817%Best | |
| $5B | 227.9 | - | +111% | |
| $39B | 126.0 | - | +207% | |
| $66B | 15.2 | 2.41 | +8% | |
| $195B | 25.3 | 8.61 | +88% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10-year return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
AKTX — Frequently Asked Questions
Quick answers to the most common questions about buying AKTX stock.
What is AKTX's P/E ratio?
Akari Therapeutics, Plc (AKTX) trailing twelve-month P/E ratio is -0.0x, based on TTM diluted EPS of $-1333.08. The 5-year average P/E is N/A and the historical range spans N/A to N/A.
Is AKTX stock overvalued or undervalued?
AKTX current P/E: -0.0x. 5-year average P/E: N/A. Percentile: N/A.
Is AKTX stock expensive?
AKTX is fairly valued relative to its own history. The current P/E of -0.0x is near the 5-year average of N/A (N/A percentile of historical range).
What is AKTX's historical P/E range?
Over the past 5 years, AKTX's P/E ratio has ranged from N/A to N/A, with a median of N/A and an average of N/A. The current P/E of -0.0x places the stock at the N/A percentile of this range. Full historical data spans 2026–2026.
How does AKTX's P/E compare to the S&P 500?
AKTX current P/E: -0.0x. S&P 500 median P/E: 25.1x.
How does AKTX's valuation compare to Healthcare peers?
Akari Therapeutics, Plc P/E of -0.0x can be benchmarked against Healthcare peers in the comparison table on this page.
What is AKTX's PEG ratio?
AKTX PEG ratio is N/A, based on a P/E of -0.0x and EPS growth of 84.3%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is AKTX's earnings yield?
AKTX earnings yield is N/A, the inverse of its -0.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.